Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing Lanbei Wang is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in mRNA-based vaccines and therapeutics. The company has developed a proprietary platform for mRNA sequence design and lipid nanoparticle (LNP) delivery systems to address unmet needs in infectious diseases and oncology. Its lead candidate is an mRNA vaccine for COVID-19, which has entered clinical trials, while its broader pipeline includes programs for RSV, influenza, and therapeutic cancer vaccines. Lanbei Wang is supported by leading healthcare investors, including GL Ventures and Legend Capital. The company aims to industrialize mRNA technology for global health applications by maintaining in-house capabilities from R&D to manufacturing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Beijing Lanbei Wang.